Page 7 - Dr Reddy's Laboratories
Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore
Deal would help Wockhardt focus on international operations, novel pipeline R&D
 "Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore")
Dr Reddy's posts Rs 570-cr net loss due to heavy impairment charge
Firm takes a Rs 1,110 crore hit with generic versions of its Nuvaring drug hitting the market; financial results run completely contra to analyst expectations
 "Dr Reddy's posts Rs 570-cr net loss due to heavy impairment charge")
Dr Reddy's Labs nears 2-year high, regains Rs 50,000 crore m-cap
In the first 11 trading days of the current calendar year, Dr Reddy's has outperformed the market by surging 6 per cent on expectations of earnings improvement.
 "Dr Reddy's Labs nears 2-year high, regains Rs 50,000 crore m-cap")
Pharma shares in focus; Dr Reddy's, Divi's, Granules hit 52-week highs
Lupin, Sun Pharmaceutical, Cadila Healthcare, Aarti Drugs and Aurobindo Pharma were up in the range of 2 per cent to 3 per cent.
 "Pharma shares in focus; Dr Reddy's, Divi's, Granules hit 52-week highs")
Dr Reddy's gets nod for amalgamation of Dr Reddy's Holdings into company
21,026 votes, which accounted for the rest 0.02 per cent, were posted against the resolution, it added
Dr Reddy's reaping benefits of domestic market focus, outperforms peers
Firm has outperformed domestic pharma market in 7 of last 8 quarters
 "Dr Reddy's reaping benefits of domestic market focus, outperforms peers")
Amneal Pharma beats Dr Reddy's in launching limited-competition drug
Amneal's EluRyng is the first generic version of this low competition drug, which the company plans to launch this month
 "Amneal Pharma beats Dr Reddy's in launching limited-competition drug")
Dr Reddy's launches cancer treatment drug Bortezomib in the US market
Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals
 "Dr Reddy's launches cancer treatment drug Bortezomib in the US market")
Dr Reddy's Labs extends gains for second straight day, hits 33-month high
Analysts at SBICAP Securities upgraded the stock with 'buy' rating and target price of Rs 3,200 per share
 "Dr Reddy's Labs extends gains for second straight day, hits 33-month high")
Dr Reddy's gives part manufacturing to China partners to tap local market
The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's
 "Dr Reddy's gives part manufacturing to China partners to tap local market")
Exposure to US market causing constant FDA scrutiny for big drug firms
Dr Reddy's was in the news for falling short of expectations during routine audits conducted by the US drug regulator
 "Exposure to US market causing constant FDA scrutiny for big drug firms")
Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad
According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact
 "Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad")
Dr Reddy's enters India's nutrition segment with a drink for diabetics
Dr Reddy's 'Celevida' is formulated to have high protein, high fibre and slowly digested carbohydrates
 "Dr Reddy's enters India's nutrition segment with a drink for diabetics")
Ranitidine recall causes Rs 40-crore dent in Dr Reddy's provisioning
An amount of Rs 17 crore is recognised as a possible refund liability (as a reduction from revenue) arising out of the company's decision to recall the said product
 "Ranitidine recall causes Rs 40-crore dent in Dr Reddy's provisioning")
Dr Reddy's posts 33% rise in profit before tax at Rs 766 crore in Q2
The drug major has reported a 26% increase in revenues at Rs 4,801 crore for Q2
Dr Reddy's Q2 net doubles to Rs 1,092 cr on one-off gains, revenues up 26%
Better top-lines numbers come in despite a flattish growth in the firm's US business.
Ranitidine cancer threat: Expect more clarity on products in coming weeks
Ranitidine sales account for 2 per cent of Strides sales and 6 per cent of its profit after tax
 "Ranitidine cancer threat: Expect more clarity on products in coming weeks")
Dr Reddy's gets 4 observations from USFDA for Srikakulam plant
Drug major Dr Reddy's on Saturday said it has received four observations from the US health regulator USFDA for its facility at Srikakulam in Andhra Pradesh. The audit of the company's API Srikakulam Plant (SEZ) by the United States Food and Drug Administration (USFDA) was completed on Friday, the Hyderabad-based pharma major said in a regulatory filing. Dr Reddy's further said that it would address the four concerns within the stipulated timeline. "The audit of our API Srikakulam Plant (SEZ), Andhra Pradesh, by the USFDA, has been completed on October 25, 2019. We have been issued a Form 483 with four observations," said Dr Reddy's. It further said: "We will address them comprehensively within the stipulated timeline." As per the US health regulator, "an FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and ...
China opens public hospitals for Dr Reddy's Laboratories generic drugs
First Indian firm to get contract for supplying generic schizophrenia drug to public hospitals there
 "China opens public hospitals for Dr Reddy's Laboratories generic drugs")
China opens public hospitals for Dr Reddy's Laboratories generic drugs
First Indian firm to get contract for supplying generic schizophrenia drug to public hospitals there
